Literature DB >> 23715694

Organ damage in high-risk patients with systemic and incomplete lupus syndromes.

Nancy J Olsen1, Maha Yousif, Azza Mutwally, Melinda Cory, Nada Elmagboul, David R Karp.   

Abstract

The objective of this study was to characterize organ damage in lupus patients enrolled in Dallas Regional Autoimmune Disease Registry (DRADR). Retrospective chart review was carried out on 99 patients with four or more diagnostic criteria for systemic lupus erythematosus (SLE) and 15 with less than four of these criteria, who were designated as having incomplete lupus erythematosus (ILE). The majority of patients (84 %) were African American or Hispanic/Latino; mean disease duration was 9.5 years. The mean damage score was 1.57 (range 0-8), and a damage score greater than 0 was present in 64 % of the patients. The ILE group had lower mean damage scores (0.67) than the SLE group (1.67; P = 0.04), explained in part by the shorter disease duration in the ILE patients (4.33 vs. 10.24 years; P = 0.003). The most prevalent damage category was renal, present in 24 % of patients. Malignancies occurred in individuals who were significantly older than those who had renal or peripheral vascular damage (P = 0.0007). The findings confirm clinical impressions that DRADR includes a high-risk lupus population. The ILE patients have less damage but also shorter disease duration, suggesting that this might represent an earlier disease stage. These results are consistent with the hypothesis that ILE patients include a subset that is likely to experience progressive organ damage. Longitudinal study of these patients has significant likelihood of tracking the changes that are correlated with disease progression to SLE.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23715694      PMCID: PMC4429789          DOI: 10.1007/s00296-013-2783-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  23 in total

1.  Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus.

Authors:  Amy E Wandstrat; Ferdicia Carr-Johnson; Valerie Branch; Hillery Gray; Anna-Marie Fairhurst; Andreas Reimold; David Karp; Edward K Wakeland; Nancy J Olsen
Journal:  J Autoimmun       Date:  2006-10-17       Impact factor: 7.094

2.  Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual.

Authors:  Luis M Vilá; Graciela S Alarcón; Gerald McGwin; Holly M Bastian; Barri J Fessler; John D Reveille
Journal:  J Rheumatol       Date:  2005-11       Impact factor: 4.666

3.  Severe lupus nephritis: racial differences in presentation and outcome.

Authors:  Stephen M Korbet; Melvin M Schwartz; Joni Evans; Edmund J Lewis
Journal:  J Am Soc Nephrol       Date:  2006-12-13       Impact factor: 10.121

4.  Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort.

Authors:  Maria I Danila; Guillermo J Pons-Estel; Jie Zhang; Luis M Vilá; John D Reveille; Graciela S Alarcón
Journal:  Rheumatology (Oxford)       Date:  2009-02-20       Impact factor: 7.580

5.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

6.  Autoantibody prevalence and lupus characteristics in a unique African American population.

Authors:  Diane L Kamen; Mia Barron; Tia M Parker; Stephanie R Shaftman; Gail R Bruner; Teresa Aberle; Judith A James; R Hal Scofield; John B Harley; Gary S Gilkeson
Journal:  Arthritis Rheum       Date:  2008-05

Review 7.  Minimising steroids in lupus nephritis--will B cell depletion pave the way?

Authors:  L Lightstone
Journal:  Lupus       Date:  2013-04       Impact factor: 2.911

8.  Assessment of damage in Korean patients with systemic lupus erythematosus.

Authors:  Yoon-Kyoung Sung; Nam Wook Hur; Jina Lee Sinskey; Dawon Park; Sang-Cheol Bae
Journal:  J Rheumatol       Date:  2007-03-15       Impact factor: 4.666

Review 9.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03

10.  Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study.

Authors:  H Laustrup; A Voss; A Green; P Junker
Journal:  Scand J Rheumatol       Date:  2009 Mar-Apr       Impact factor: 3.641

View more
  12 in total

Review 1.  Preclinical systemic lupus erythematosus.

Authors:  Julie M Robertson; Judith A James
Journal:  Rheum Dis Clin North Am       Date:  2014-09-02       Impact factor: 2.670

2.  We need better classification and terminology for "people at high risk of or in the process of developing lupus".

Authors:  Karen H Costenbader; Peter H Schur
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-05       Impact factor: 4.794

3.  Organ damage in patients with incomplete lupus syndromes: from a Chinese academic center.

Authors:  Zhen Chen; Meng-Tao Li; Dong Xu; Xiao-Mei Leng; Qian Wang; Xin-Ping Tian; Shang-Zhu Zhang; Yan Zhao; Xiao-Feng Zeng
Journal:  Clin Rheumatol       Date:  2015-02-18       Impact factor: 2.980

4.  Screening characteristics for enrichment of individuals at higher risk for transitioning to classified SLE.

Authors:  K A Young; M E Munroe; J M Guthridge; D L Kamen; G S Gilkensen; J B Harley; M H Weisman; D R Karp; D J Wallace; J A James; J M Norris
Journal:  Lupus       Date:  2019-03-07       Impact factor: 2.911

Review 5.  Preclinical lupus.

Authors:  Rebecka Bourn; Judith A James
Journal:  Curr Opin Rheumatol       Date:  2015-09       Impact factor: 5.006

6.  Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls.

Authors:  Teresa Aberle; Rebecka L Bourn; Melissa E Munroe; Hua Chen; Virginia C Roberts; Joel M Guthridge; Krista Bean; Julie M Robertson; Kathy L Sivils; Astrid Rasmussen; Meghan Liles; Joan T Merrill; John B Harley; Nancy J Olsen; David R Karp; Judith A James
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-11-14       Impact factor: 4.794

Review 7.  A highlight from the LUPUS 2014 meeting: eight great ideas.

Authors:  Jill P Buyon; Phillip Cohen; Joan T Merrill; Gary Gilkeson; Mariana Kaplan; Judith James; W Joseph McCune; Sasha Bernatsky; Keith Elkon
Journal:  Lupus Sci Med       Date:  2015-06-30

8.  Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences.

Authors:  Íñigo Rúa-Figueroa; Patricia Richi; Francisco Javier López-Longo; María Galindo; Jaime Calvo-Alén; Alejandro Olivé-Marqués; Estíbaliz Loza-Santamaría; Sabina Pérez Vicente; Celia Erausquin; Eva Tomero; Loreto Horcada; Esther Uriarte; Ana Sánchez-Atrio; José Rosas; Carlos Montilla; Antonio Fernández-Nebro; Manuel Rodríguez-Gómez; Paloma Vela; Ricardo Blanco; Mercedes Freire; Lucía Silva; Elvira Díez-Álvarez; Mónica Ibáñez-Barceló; Antonio Zea; Javier Narváez; Víctor Martínez-Taboada; José Luis Marenco; Mónica Fernández de Castro; Olaia Fernández-Berrizbeitia; José Ángel Hernández-Beriain; Marian Gantes; Blanca Hernández-Cruz; José J Pérez-Venegas; Ángela Pecondón; Carlos Marras; Patricia Carreira; Gema Bonilla; Vicente Torrente; Iván Castellví; Juan Alegre; Mireia Moreno; Enrique Raya; Paloma García de la Peña; Tomás Vázquez; Ángeles Aguirre; Víctor Quevedo; José M Pego-Reigosa
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

9.  Clinical and Immunologic Profiles in Incomplete Lupus Erythematosus and Improvement with Hydroxychloroquine Treatment.

Authors:  Nancy J Olsen; Carl McAloose; Jamie Carter; Bobby Kwanghoon Han; Indu Raman; Quan-Zhen Li; Duanping Liao
Journal:  Autoimmune Dis       Date:  2016-12-28

10.  An Observational Cross-Sectional Study of Varied Clinical Manifestations of Connective Tissue Disorders and their Association with Antinuclear Antibodies in a Tertiary Care Center.

Authors:  Rana Abdul Kadiru; Spandana P Hegde; Manjunath M Shenoy
Journal:  Indian Dermatol Online J       Date:  2019 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.